The PennZone

PHILADELPHIA, June 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several investor conferences in June 2023. These investor conferences include:

Jefferies Global Healthcare Conference

• Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
• Friday, June 9 at 10:00 am EDT.
• New York City

Baird's Biotech Discovery Series

• Steven Kelly, President and Chief Executive Officer, and Michael Klichinsky, PhD, Co-Founder and Chief Scientific Officer, will participate in a fireside chat.
• Wednesday, June 21 at 1:30 pm EDT.
• Virtual

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts will be archived at the Company's past events section of the Investor Relations webpage for a limited time following the event.

About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

More on The PennZone

• Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
• Primeindexer Google indexing platform launched by SEO Danmark APS
• Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
• Talentica Announces Winners of Multi-Agent Hackathon 2026
• Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth

Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials, and participation by Carisma in future healthcare industry and investor conferences. The words ""anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in Exhibit 99.3 to Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's most recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

More on The PennZone

• Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
• Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
• Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
• Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
• 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies

Media Contact:
Julia Stern
(763) 350-5223
[email protected]

Investor Contact:
[email protected]

SOURCE Carisma Therapeutics Inc.

---

Show All News | Report Violation